SK plasma enters ADC cancer drug development with AIMEDBIO partnership

CAR-T Digest - August 2020

09 June 2025: SK plasma enters ADC cancer drug development with AIMEDBIO partnership 

SK plasma has partnered with AIMEDBIO to co-develop an antibody-drug conjugate (ADC) targeting ROR1, marking SK plasma entry into ADC-based cancer therapy development. AIMEDBIO will handle research and discovery, while SK plasma will manage clinical development and commercialization
The collaboration focuses on creating a next-gen ADC designed to selectively deliver cytotoxic agents to ROR1-expressing tumor cells, aiming for high efficacy with reduced toxicity
AIMEDBIO brings proprietary ADC platforms and deep oncology expertise, while SK plasma expands its biopharma footprint, following its previous investment in CAR-T developer CuureCell